Sales for the second quarter ended at MNOK 137.4 (MNOK 117.5), an increase of
16.9%. Sales for first half ended at MNOK 266.6 (MNOK 233.6), an increase of
14.1%.

Currency neutral sales of own products was up 4.0% for the quarter and 2.5% for
the first half.

Operating profit (EBIT) for the quarter is up 13.1% and ended at MNOK 42.2, an
EBIT margin at 30.7% (MNOK 37.3 an EBIT margin at 31.8%). For the first half
EBIT is up 6.9% and ended at MNOK 75.7 an EBIT margin at 32.6% for the first
half (MNOK 70.8 an EBIT margin at 35.3%).

Medistim established direct sales organizations in both Canada and China in Q2
and continues to strengthen its organization worldwide.

Medistim announced its participation in a groundbreaking cardiac surgery trial
dedicated to women, ROMA-W.

A dividend of NOK 4.50 per share, a total of MNOK 82.2, was paid 5th of May.